Catalent employee John Tomtishen will participate in a webinar hosted by BioPharma Dive on preparing for the next decade in cell therapy and evolving CMC strategies.
Public source
Publisher name
Public post
Next week, I will be taking part in a webinar hosted by BioPharma Dive on “Preparing the for next decade in cell therapy: How sponsors can evolve their CMC strategies fo…
Company
Catalent
- Industry
- Pharmaceutical Manufacturing
- Location
- Tampa, US
- Company size
- 10,001+ employees
About Catalent
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
See moreLatest activity
Latest activity from Catalent
32 signals
People
Catalent welcomed President and CEO Alessandro Maselli to teams in Schorndorf, Eberbach, and Limoges across the European network.
Legal & Regulatory
Catalent supports Definium Therapeutics in receiving its second FDA Breakthrough Therapy designation for DT120 ODT for the treatment of major depressive disorder (MDD).
Research & Knowledge
Catalent and Roquette published an article in ONdrugDelivery exploring best practices for protecting moisture-sensitive inhalation products, including spray drying, powder collection, encapsulation, and blister packaging.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Outsourced Pharma
Outsourced Pharma attended the ADC Capabilities Update hosted by Catalent to learn about the integrated ADC and bioconjugate development platform spanning the full product lifecycle.
Presence & Recognition
Kincell Bio
Kincell Bio hosted an on-demand webinar titled Outsourced Pharma Cell Therapy Capabilities Update featuring Stewart McNaull, PhD, Chief Commercial Officer, and Matt Haines, Chief Operations Officer, discussing cell therapy CDMO considerations.
Presence & Recognition
Syner-G
Syner-G employee Stacy Plum, PhD, SVP, Pharmaceutical Development and Head of Biologics will participate in the Cell & Gene Therapy Insights webinar on September 9, 2026, discussing precision medicine strategies.
Presence & Recognition
Patheon
Patheon featured Jennifer Cannon, Sector Commercial President, BioPharma Services, in a webinar hosted by Life Science Connect discussing onshoring strategies and flexible manufacturing models.
Presence & Recognition
Minaris